Hoeger Bement M, St Marie B, Nordstrom T, Christensen N, Mongoven J, Koebner I, Fishman S, Sluka K. An Interprofessional consensus of core competencies for prelicensure education in pain management: curriculum application for physical therapy. Phys Ther. 2014;94:451–64.
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380–7.
Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira B. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836–43.
Buchbinder R, Tulder M von, Öberg B, Menezes Costa L, Woolf A, Schoene M, Croft P, Lancet Low Back Pain Series WG. Low back pain: a call for action. Lancet. 2018;391: 2384–2388.
Behrman M, Linder R, Assadi AH, Stacey BR, Backonja M-M. Classification of patients with pain based on neuropathic pain symptoms: comparison of an artificial neural network against an established scoring system. Eur J Pain. 2007;11:370–6.
Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, Harris I, Day RO, Billot L, Pik K, Jan S, Lin C-WC. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376:1111–20.
Derry S, Bell R F, Straube S, Wiffen P J, Aldington D, Moore R A. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1: CD007–076.
Yu X, Liu T, Zhao D, Yang K, Zhang X, Zhang M, Zhang S, Huang W, Wu B, Li J. Efficacy and safety of pregabalin in neuropathic pain followed spinal cord injury: a review and meta-analysis of randomized controlled trials. Clin J Pain. 2019;35:272–8.
Canos A, Cort L, Fernández Y, Rovira V, Pallarés J, Barberá M, Morales-Suárez-Varela M. Preventive analgesia with pregabalin in neuropathic pain from “failed back surgery syndrome”: assessment of sleep quality and disability. Pain Med. 2016;17:344–52.
Ueda H. Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. Pain. 2017;158:S55–65.
Uranbileg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A, Kano K, Ikeda H, Yamada Y, Sumitani M, Sekiguchi M, Aoki J, Yatomi Y. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: a study using a rat cauda equina compression model. Sci Rep. 2019;9:16578.
Tsuchida R, Tanabe Y, Nishizawa D, Ikeda K, Abe H, Inoue R, Kurano M, Yatomi Y, Tamura K, Takano T, Shimizu C, Uchida K, Sumitani M. Genetic polymorphisms of lysophosphatidic acid receptor 1 are associated with the onset of taxane-induced peripheral neuropathy. Br J Anaesth. 2021;127:e43–6.
Hayakawa K, Kurano M, Ohya J, Oichi T, Kano K, Nishikawa M, Uranbileg B, Kuwajima K, Sumitani M, Tanaka S, Aoki J, Yatomi Y, Chikuda H. Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis. Sci Rep. 2019;9:9144.
Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki K, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep. 2021;11:3984.
Kuwajima K, Sumitani M, Kurano M, Kano K, Nishikawa M, Uranbileg B, Tsuchida R, Ogata R, Aoki J, Yatomi Y, Yamada Y. Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study. PLoS ONE. 2018;13: e0207310.
Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000; 478: 159–65
Ma L, Nagai J, Chun J, Ueda H. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model. Mol Pain. 2013;17(9):29.
Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.
Sakai E, Kurano M, Morita Y, Aoki J, Yatomi Y. Establishment of a measurement system for sphingolipids in the cerebrospinal fluid based on liquid chromatography-tandem mass spectrometry, and its application in the diagnosis of carcinomatous meningitis. J Appl Lab Med. 2020;5:656–70.
Morita Y, Kurano M, Sakai E, Nishikawa M, Sawabe M, Aoki J, Yatomi Y. Evaluation of lysophospholipid measurement in cerebrospinal fluid samples using liquid chromatography-tandem mass spectrometry. Lipids. 2019;54:487–500.
Inoue R, Sumitani M, Ogata T, Chikuda H, Matsubara T, Kato S, Shimojo N, Uchida K, Yamada Y. Direct evidence of central nervous system axonal damage in patients with postoperative delirium: a preliminary study of pNF-H as a promising serum biomarker. Neurosci Lett. 2017;653:39–44.
Natori A, Ogata T, Sumitani M, Kogure T, Yamauchi T, Yamauchi H. Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment. Clin Cancer Res. 2015;21:1348–52.
Sumitani M, Ogata T, Natori A, Hozumi J, Shimojo N, Kida K, Yamauchi H, Yamauchi T. Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. Biomed Rep. 2016;4:758–60.
Ohya J, Chikuda H, Kato S, Hayakawa K, Oka H, Takeshita K, Tanaka S, Ogata T. Elevated levels of phosphorylated neurofilament heavy subunit in the cerebrospinal fluid of patients with lumbar spinal stenosis: preliminary findings. Spine J. 2015;15:1587–92.
Michalcczyk A, Budkowska M, Dolegowska B, Chlubek D, Safranow K. Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters. Lipids Health Dis. 2017;16:140.
Inoue M, Ma L, Aoki J, Chun J, Ueda H. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain. 2008;4:6.
Inoue M, Rashid MH, Fujita R, Contos JJA, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10:712–8.
Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther. 2006;109:57–77.
Hemmings DG, Brindley DN. Signalling by lysophosphatidate and its health implications. Essays Biochem. 2020;64:547–63.
Yu P, Agbaegbu C, Malide DA, Wu X, Katagiri Y, Hammer JA, Geller HM. Cooperative interactions of LPPR family members in membrane localization and alteration of cellular morphology. J Cell Sci. 2015;128:3210–22.
CAS PubMed PubMed Central Google Scholar
Strauss U, Bräuer AU. Current views on regulation and function of plasticity-related genes (PRGs/LPPRs) in the brain. Biochim Biophys Acta. 2013;1831:133–8.
Ma L, Nagai J, Chun J, Ueda H. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model. Mol Pain. 2013;9:29.
Matsuoka H, Tanaka H, Sayanagi J, Iwahashi T, Suzuki K, Nishimoto S, Okada K, Murase T, Yoshikawa H. Neurotropin ® accelerates the differentiation of schwann cells and remyelination in a rat lysophosphatidylcholine-induced demyelination model. Int J Mol Sci. 2018;19:516.
Sattikar A, Dowling MR, Rosethorne EM. Endogenous lysophosphatidic acid (LPA1) receptor agonists demonstrate ligand bias between calcium and ERK signaling pathways in human lung fibrosis. Br J Pharmacol. 2017;174:227–37.
留言 (0)